We are analyzing https://link.springer.com/article/10.1007/s00262-020-02729-y.

Title:
Combination therapies utilizing neoepitope-targeted vaccines | Cancer Immunology, Immunotherapy
Description:
Clinical successes have been achieved with checkpoint blockade therapy, which facilitates the function of T cells recognizing tumor-specific mutations known as neoepitopes. It is a reasonable hypothesis that therapeutic cancer vaccines targeting neoepitopes uniquely expressed by a patient’s tumor would prove to be an effective therapeutic strategy. With the advent of high-throughput next generation sequencing, it is now possible to rapidly identify these tumor-specific mutations and produce therapeutic vaccines targeting these patient-specific neoepitopes. However, initial reports suggest that when used as a monotherapy, neoepitope-targeted vaccines are not always sufficient to induce clinical responses in some patients. Therefore, research has now turned to investigating neoepitope vaccines in combination with other cancer therapies, both immune and non-immune, to improve their clinical efficacies.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Science
Health & Fitness
Education

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We see no obvious way the site makes money.

Not all websites are made for profit; some exist to inform or educate users. Or any other reason why people make websites. And this might be the case. Link.springer.com might have a hidden revenue stream, but it's not something we can detect.

Keywords {🔍}

vaccines, pubmed, vaccine, cancer, cells, tumor, article, neoepitope, neoepitopes, combination, google, scholar, cas, responses, immune, mice, clinical, patients, studies, nct, central, therapy, therapies, checkpoint, targeting, combining, immunotherapy, monotherapy, potential, vaccination, response, melanoma, preclinical, treated, therapeutic, peptides, antipd, agents, additionally, inhibitors, tcell, induced, immunol, mutations, treatment, growth, immunity, tumors, cell, survival,

Topics {✒️}

tumor-targeted immunocytokine nhs-il12 full-length ny-eso-1 protein pre-existing t-cell responses predominantly t-cell–mediated responses neoepitope-specific t-cell responses rna-based poly-neoepitope vaccine great ape–derived adenovirus tumor-infiltrating neoepitope-specific cd8 article download pdf robust neoepitope-specific cytotoxic induced immune-cell infiltration t-cell response induced murine braf-mutant melanoma rna-based vaccines led neoepitope-derived multipeptide vaccines vaccine-draining lymph node albumin/albumin-binding vaccine vaccine-induced neoepitope-specific intratumoral t-cell repertoire tumor-specific immunotherapy targeting induce b-cell responses induced smc3-specific cd8 cell-mediated tumor control combining neoepitope-targeting vaccines myeloid-derived suppressor cells high-affinity tumor-specific neoepitope-targeted vaccines pd-1/programmed death-ligand 1 related subjects fda-approved oncolytic virus tumor necrosis factor k-ras-derived peptides anti-cancer immune response high-throughput genomic sequencing murine pancreatic cancer tyrosinase-related protein antigen-specific ifnγ production personalized cancer immunotherapy resulting peptide-hla complex ott pa therapeutic cancer vaccines therapeutic neoepitope vaccines induced epitope spreading taa-targeting vaccines combined t-cell targeting vivo–loaded dendritic cells immunosuppressive tumour network anti-tumor immune cells cancer therapeutic potency sting-based adjuvant

Questions {❓}

Lasek W, Zagozdzon R, Jakobisiak M (2014) Interleukin 12: still a promising candidate for tumor immunotherapy?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Combination therapies utilizing neoepitope-targeted vaccines
         description:Clinical successes have been achieved with checkpoint blockade therapy, which facilitates the function of T cells recognizing tumor-specific mutations known as neoepitopes. It is a reasonable hypothesis that therapeutic cancer vaccines targeting neoepitopes uniquely expressed by a patient’s tumor would prove to be an effective therapeutic strategy. With the advent of high-throughput next generation sequencing, it is now possible to rapidly identify these tumor-specific mutations and produce therapeutic vaccines targeting these patient-specific neoepitopes. However, initial reports suggest that when used as a monotherapy, neoepitope-targeted vaccines are not always sufficient to induce clinical responses in some patients. Therefore, research has now turned to investigating neoepitope vaccines in combination with other cancer therapies, both immune and non-immune, to improve their clinical efficacies.
         datePublished:2020-10-08T00:00:00Z
         dateModified:2020-10-08T00:00:00Z
         pageStart:875
         pageEnd:885
         license:http://creativecommons.org/licenses/by/4.0/
         sameAs:https://doi.org/10.1007/s00262-020-02729-y
         keywords:
            Neoepitope vaccine
            Combination therapy
            Checkpoint blockade
            Epitope spreading
            Oncology
            Immunology
            Cancer Research
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-020-02729-y/MediaObjects/262_2020_2729_Fig1_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-020-02729-y/MediaObjects/262_2020_2729_Fig2_HTML.png
         isPartOf:
            name:Cancer Immunology, Immunotherapy
            issn:
               1432-0851
               0340-7004
            volumeNumber:70
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer Berlin Heidelberg
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Karin L. Lee
               affiliation:
                     name:National Institutes of Health
                     address:
                        name:Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Jeffrey Schlom
               url:http://orcid.org/0000-0001-7932-4072
               affiliation:
                     name:National Institutes of Health
                     address:
                        name:Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, USA
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:Duane H. Hamilton
               affiliation:
                     name:National Institutes of Health
                     address:
                        name:Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, USA
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:1
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Combination therapies utilizing neoepitope-targeted vaccines
      description:Clinical successes have been achieved with checkpoint blockade therapy, which facilitates the function of T cells recognizing tumor-specific mutations known as neoepitopes. It is a reasonable hypothesis that therapeutic cancer vaccines targeting neoepitopes uniquely expressed by a patient’s tumor would prove to be an effective therapeutic strategy. With the advent of high-throughput next generation sequencing, it is now possible to rapidly identify these tumor-specific mutations and produce therapeutic vaccines targeting these patient-specific neoepitopes. However, initial reports suggest that when used as a monotherapy, neoepitope-targeted vaccines are not always sufficient to induce clinical responses in some patients. Therefore, research has now turned to investigating neoepitope vaccines in combination with other cancer therapies, both immune and non-immune, to improve their clinical efficacies.
      datePublished:2020-10-08T00:00:00Z
      dateModified:2020-10-08T00:00:00Z
      pageStart:875
      pageEnd:885
      license:http://creativecommons.org/licenses/by/4.0/
      sameAs:https://doi.org/10.1007/s00262-020-02729-y
      keywords:
         Neoepitope vaccine
         Combination therapy
         Checkpoint blockade
         Epitope spreading
         Oncology
         Immunology
         Cancer Research
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-020-02729-y/MediaObjects/262_2020_2729_Fig1_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-020-02729-y/MediaObjects/262_2020_2729_Fig2_HTML.png
      isPartOf:
         name:Cancer Immunology, Immunotherapy
         issn:
            1432-0851
            0340-7004
         volumeNumber:70
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer Berlin Heidelberg
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Karin L. Lee
            affiliation:
                  name:National Institutes of Health
                  address:
                     name:Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Jeffrey Schlom
            url:http://orcid.org/0000-0001-7932-4072
            affiliation:
                  name:National Institutes of Health
                  address:
                     name:Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, USA
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:Duane H. Hamilton
            affiliation:
                  name:National Institutes of Health
                  address:
                     name:Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, USA
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:1
["Periodical","PublicationVolume"]:
      name:Cancer Immunology, Immunotherapy
      issn:
         1432-0851
         0340-7004
      volumeNumber:70
Organization:
      name:Springer Berlin Heidelberg
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:National Institutes of Health
      address:
         name:Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, USA
         type:PostalAddress
      name:National Institutes of Health
      address:
         name:Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, USA
         type:PostalAddress
      name:National Institutes of Health
      address:
         name:Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, USA
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Karin L. Lee
      affiliation:
            name:National Institutes of Health
            address:
               name:Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, USA
               type:PostalAddress
            type:Organization
      name:Jeffrey Schlom
      url:http://orcid.org/0000-0001-7932-4072
      affiliation:
            name:National Institutes of Health
            address:
               name:Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, USA
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:Duane H. Hamilton
      affiliation:
            name:National Institutes of Health
            address:
               name:Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, USA
               type:PostalAddress
            type:Organization
PostalAddress:
      name:Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, USA
      name:Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, USA
      name:Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, USA

External Links {🔗}(239)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

4.16s.

LINK . SPRINGER . COM {}